clinical manifestation
Recently Published Documents


TOTAL DOCUMENTS

1909
(FIVE YEARS 756)

H-INDEX

55
(FIVE YEARS 13)

2022 ◽  
Vol 10 (1) ◽  
pp. 1-5
Author(s):  
Aran A Groover ◽  
Natalia A Huang

Miliary Tuberculosis (TB) usually has an insidious clinical manifestation including fever, weight loss, night sweats, and little in the way of localizing symptoms or signs. There may be concurrent TB meningitis with associated symptoms. A 35-year old male has known case of pulmonary TB and HCV before three years ago. Presented to emergency department with Fever since 3-weeks ago, abdomen pain, headache since 10 days.


2022 ◽  
Vol 9 (1) ◽  
pp. 231-238
Author(s):  
Putu Eka Ratna Setia Rahayu ◽  
Gusti Ayu Vina Mery Giovani

Background/Aim: Morbus Hansen (MH) is a chronic infectious disease caused by Mycobacterium leprae. The disease has an average incubation period of 3-5 years. Morbus Hansen (MH) has various clinical, microbiological and histopathological features. In the following, a new case of MH is reported with a clinical manifestation of Borderline Tuberculoid (BT) type MH. The patient was treated with the MDT MB regimen for 3 months and had clinical improvement. Case Report: A 23-year-old boy with complaints of sudden feeling of heat, tingling and cramping from the tip of his right foot to the sole of his right foot. He also complaining about black lesions on both hands, right elbow, face, chest and back. The diagnosis of gout, fungus and dermatitis can be ruled out after microscopic examination of AFB on the right, left ear lobe, and foot lesions showed negative results and histopathological examination results showed Morbus Hansen type BT. The risk factor for contracting Morbus Hansen is the patient has lived in a dormitory for 2.5 years and it is known that there are people who suffer from a similar disease in that environment. The patient was treated using a multibacillary regimen for 3 months and the lesions improved and the numbness decreased. Treatment plan during the case for 12-18 months. This case is unique due to the clinical manifestation has not significant characteristic for MH, AFB is not found from ear lobe smear. MH established after skin biopsy done. Conclusion: It was reported that one MH case with TB for 3 months had clinical improvement, with plans to continue treatment for 12-18 months. Keywords: Borderline Tuberculoid; Morbus Hansen, Multibacillary.


2022 ◽  
pp. 18-26
Author(s):  
Muskaan Sachdeva ◽  
Monica Shah ◽  
Afsaneh Alavi

2021 ◽  
Vol 24 (10) ◽  
pp. 304-308
Author(s):  
Caterina Bacci ◽  
Sara Picariello ◽  
Francesco Vierucci ◽  
Carlo Mazzatenta ◽  
Angelina Vaccaro

Erythema nodosum is a panniculitis that can be triggered by many different stimuli. The paper describes the case of a child who presented with erythema nodosum as the unique clinical manifestation of cat scratch disease. Bartonella henselae infection usually presents with non-tender papule in the scratch line followed by subsequent onset of regional lymphadenopathy eventually associated with systemic symptoms. It can also present with atypical manifestation, such as erythema nodosum. The heterogeneity of the clinical presentations makes the disease to be underdiagnosed, whereby it is important to recognize atypical manifestations. Therefore, it is recommended to include Bartonella henselae serology in the diagnostic evaluation of erythema nodosum.


2021 ◽  
Vol 23 (1) ◽  
pp. 390
Author(s):  
Iwona Ben-Skowronek ◽  
Joanna Sieniawska ◽  
Emilia Pach ◽  
Wiktoria Wrobel ◽  
Anna Skowronek ◽  
...  

The autoimmune reaction against the beta cells of the pancreatic islets in type 1 diabetes mellitus (T1DM) patients is active in prediabetes and during the development of the clinical manifestation of T1DM, but it decreases within a few years of the clinical manifestation of this disease. A key role in the pathogenesis of T1DM is played by regulatory T cell (Treg) deficiency or dysfunction. Immune interventions, such as potential therapeutic applications or the induction of the Treg-cell population in T1DM, will be important in the development of new types of treatment. The aim of this study was to evaluate innovative immune interventions as treatments for T1DM. After an evaluation of full-length papers from the PubMed database from 2010 to 2021, 20 trials were included for the final analysis. The analysis led to the following conclusions: Treg cells play an important role in the limitation of the development of T1DM, the activation or application of Tregs may be more effective in the early stages of T1DM development, and the therapeutic use of Treg cells in T1DM is promising but requires long-term observation in a large group of patients.


Author(s):  
Emilia Majsiak ◽  
Magdalena Choina ◽  
Alastair M. Gray ◽  
Mariusz Wysokinski ◽  
Bożena Cukrowska

The diagnosis of celiac disease (CD) may be delayed due to non-specific clinical symptoms. The aim of the study was to evaluate the clinical manifestation and diagnostic process of CD in Polish children and adults. Methods: The members of the Polish Coeliac Society (n=2 500) were asked to complete a questionnaire on socio-demographic factors, clinical and diagnostic aspects of CD. The analysis was based on 796 responses from patients with confirmed CD diagnosis, and included 224 (28.1%) children and 572 (71.9%) adults. Results: The mean duration of symptoms prior to CD diagnosis in children was significantly shorter than in adults (p < 0.001), and amounted to 3.1 and 9 years respectively. The most frequent symptoms before CD diagnosis were abdominal pain and bloating in children (70.4%), and chronic fatigue in adults (74.5%). Although almost all CD patients claimed to strictly avoid gluten after CD diagnosis, symptoms were still present in the majority of these respondents. No comorbid diseases were reported by 29.8% of children and by 11.7% of adults (p < 0.001). Conclusions: The results indicate that CD diagnosis is delayed in Poland, espe-cially in adults, and clinicians should be aware of the diversity in CD presentation.


Glia ◽  
2021 ◽  
Author(s):  
Marja Koskuvi ◽  
Šárka Lehtonen ◽  
Kalevi Trontti ◽  
Meike Keuters ◽  
Ying‐Chieh Wu ◽  
...  

Immunotherapy ◽  
2021 ◽  
Author(s):  
Agnieszka Dybała ◽  
Alvise Sernicola ◽  
Vito Gomes ◽  
Giorgia Carnicelli ◽  
Rovena Muharremi ◽  
...  

Dupilumab-related head and neck dermatitis is an increasingly reported clinical manifestation occurring in 4–10% of patients on dupilumab that was apparently not reported in clinical trials. Out of 62 adult patients treated with dupilumab for atopic dermatitis in the authors' center, four cases (6%) of head and neck dermatitis were observed, for which a skin biopsy was obtained. Onset occurred between 8 and 24 weeks after initiation of dupilumab, and the reaction resolved after 8–12 weeks. Histopathology and immunohistochemical findings support the authors' hypothesis that facial redness may be a toxic effect induced by dupilumab, although its pathogenesis still requires further investigation.


Sign in / Sign up

Export Citation Format

Share Document